

From: Annette Grant <Annette.Grant@ks.gov>
Date: Thursday, March 2, 2017 at 11:30 AM
To: Annette Grant <Annette.Grant@ks.gov>
Subject: KANSAS CLARIFICATIONS for Medicaid PDL agenda and bidding

Good Morning,

In light of the emails I have been getting, I am going to address the answers to those email questions to all of you.

1. I will not address new classes/groupings of drugs until after the April DUR meeting. I will then determine the bid rotation for those new classes. Then I will send out bid requests for those new classes/groupings based on when that rotation falls. The new drug classes/groupings may fall all in the same rotation or different rotations. I have not decided that yet.
2. The PDL website posting one-time exception to the new drug to a class or new PDL class-supplemental bid process, states that for those new drugs or new classes from the March 8, 2017 PDL meeting, the state will send out a separate bid request for those drugs. Manufacturers do not have to send a bid to the state within 15 days of the March 8, 2017 PDL meeting. Again, this is a one-time exception.

The PDL bid submission process one-time website posting does not mention drugs already currently in that class. When a new class/grouping is formed from existing classes, there is a transition period. I will do my best to direct you through that transition.

The new PDL organization will be **mostly** about alphabetical order, not big headings and sub-headings. There is a myriad of options to PDL organization- route, indication, drug class, formal name, common name, etc.

It is for the state to present the rationale to the state PDL committee and let the PDL committee make the final decision. If you want to understand more, please attend the PDL meeting.

Regular supplemental bidding rotation will not directly be affected by the March 8, 2017 PDL meeting. I will send out the regular rotation bid request based on the current PDL classes. Because of the emails I received, I did not send yesterday.

For this next rotation, the bid request covers classes that the contract period is June or later. This is long past the PDL and DUR meetings. This allows you time to evaluate the situation and your bid prior to sending.

None of the drugs for the bids due March 1, 2017 were on the PDL agenda. For those on the April bids due, I would consider the decisions made at the March 8, 2017 PDL meeting, when preparing your bid.

I hope this helps your understanding of the PDL changes.

Thank you,
Annette

Annette Grant, RPh
Pharmacy Program Manager
Division of Health Care Finance

Kansas Department of Health and Environment
900 SW Jackson St., Suite 900-N
Topeka, KS 66612
Phone: 785-296-8406
Fax: 785-296-4813